https://www.regulatoryrapporteur.org/january-2025-contents/820.article 2025-03-03T13:21:50.537Z https://www.regulatoryrapporteur.org/industry-news/ec-announces-evaluation-of-medical-device-and-ivd-regulations/821.article 2025-01-09T16:47:49.910Z https://www.regulatoryrapporteur.org/editorials/biologics-development-overcoming-regulatory-hurdles/819.article 2025-03-03T13:22:34.223Z https://www.regulatoryrapporteur.org/biologics/considerations-for-generics-developers-moving-into-the-field-of-biosimilars/814.article 2025-01-10T08:49:42.170Z https://www.regulatoryrapporteur.org/unique-aspects-of-biologic-reference-standards/811.article 2025-02-07T11:25:03.470Z https://www.regulatoryrapporteur.org/considerations-in-the-development-of-allogenic-and-autologous-cell-therapies/818.article 2026-03-04T17:20:46.120Z https://www.regulatoryrapporteur.org/addressing-the-challenges-of-implementing-the-common-technical-document-in-brazil/816.article 2025-01-10T08:52:32.780Z https://www.regulatoryrapporteur.org/overview-of-chemical-generics-registration-in-china-challenges-for-overseas-applicants/813.article 2025-01-10T08:53:38.657Z https://www.regulatoryrapporteur.org/artificial-intelligence/the-role-of-artificial-intelligence-in-regulatory-affairs/817.article 2025-01-16T17:26:21.897Z https://www.regulatoryrapporteur.org/industry-news/ich-releases-m15-guideline-on-model-informed-drug-development/822.article 2025-01-21T11:03:28.020Z https://www.regulatoryrapporteur.org/industry-news/fda-releases-new-draft-guidance-on-assessing-artificial-intelligence-data/823.article 2025-01-17T17:35:36.120Z https://www.regulatoryrapporteur.org/industry-news/mhra-issues-guidance-on-post-market-surveillance-regulation-in-great-britain/824.article 2025-01-17T17:03:47.237Z https://www.regulatoryrapporteur.org/podcasts/regrappod--inconversation-with-the-uk-epi-task-force/837.article 2025-12-11T12:40:56.977Z https://www.regulatoryrapporteur.org/february-2025-contents/839.article 2025-03-03T15:13:28.047Z https://www.regulatoryrapporteur.org/editorials/medical-device-regulation-challenges-innovation-and-the-future/840.article 2025-05-22T08:16:17.863Z https://www.regulatoryrapporteur.org/medical-devices/the-eu-medical-device-regulation-balancing-innovation-with-regulation/832.article 2026-02-03T18:07:30.727Z https://www.regulatoryrapporteur.org/implications-of-the-eus-ai-act-for-medical-devices-and-in-vitro-diagnostic-medical-devices/833.article 2025-03-06T09:19:36.370Z https://www.regulatoryrapporteur.org/an-introduction-to-the-medical-device-single-audit-program/838.article 2025-02-07T12:33:21.780Z https://www.regulatoryrapporteur.org/regulatory-procedures/immunological-considerations-in-the-development-of-novel-vaccines/834.article 2025-02-10T10:41:54.053Z https://www.regulatoryrapporteur.org/an-industry-perspective-on-the-use-of-patient-experience-data-in-medicines-development-is-further-action-needed-from-european-regulators/835.article 2025-03-05T13:39:30.050Z https://www.regulatoryrapporteur.org/regulatory-procedures/regulatory-strategy-implications-for-foetal-medicine/836.article 2025-05-14T09:50:45.050Z https://www.regulatoryrapporteur.org/industry-news/pharmacies-told-to-follow-gphc-guidance-on-prescription-only-weight-loss-medicine/842.article 2025-02-17T16:40:54.230Z https://www.regulatoryrapporteur.org/industry-news/ema-accepts-new-guidelines-on-investigational-atmps/843.article 2025-02-17T12:57:57.160Z https://www.regulatoryrapporteur.org/industry-news/ema-establishes-new-standard-procedure-for-high-risk-medical-devices/844.article 2025-02-17T13:24:09.370Z https://www.regulatoryrapporteur.org/editorials/data-and-ai-readiness-research-and-real-world-impact/852.article 2025-04-03T14:52:52.467Z https://www.regulatoryrapporteur.org/march-2025-contents/853.article 2025-04-03T15:43:06.093Z https://www.regulatoryrapporteur.org/organising-high-quality-research-and-development-data-for-success/847.article 2025-03-07T11:27:48.303Z https://www.regulatoryrapporteur.org/ai-adoption-readiness-current-status-and-trends-in-regulatory-organisations/846.article 2025-04-25T08:51:42.207Z https://www.regulatoryrapporteur.org/artificial-intelligence-and-post-market-surveillance/848.article 2025-03-07T12:04:10.233Z https://www.regulatoryrapporteur.org/using-data-to-drive-regulatory-performance/850.article 2025-03-07T12:05:04.543Z https://www.regulatoryrapporteur.org/immunological-considerations-in-the-development-of-novel-vaccines/849.article 2025-04-09T11:06:44.430Z https://www.regulatoryrapporteur.org/the-eus-health-technology-assessment-regulation-overview-and-considerations-for-regulatory-teams/851.article 2026-04-07T14:57:23.917Z https://www.regulatoryrapporteur.org/industry-news/mhra-approves-nemolizumab-for-eczema-patients-in-the-uk/855.article 2025-03-07T15:54:48.080Z https://www.regulatoryrapporteur.org/industry-news/mhra-appoints-new-chief-executive-officer/858.article 2025-03-13T15:42:53.960Z https://www.regulatoryrapporteur.org/industry-news/uk-life-science-sector-calls-for-more-diverse-workforce-skills-to-secure-future-growth/859.article 2025-03-14T16:16:33.557Z https://www.regulatoryrapporteur.org/rui-santos-ivo-elected-as-new-chair-of-the-ema-management-board/868.article 2025-04-01T16:01:38.830Z https://www.regulatoryrapporteur.org/editorials/africa-and-the-mena-region-opportunities-for-growth/869.article 2025-05-01T13:54:56.980Z https://www.regulatoryrapporteur.org/april-2025-contents/870.article 2025-08-04T09:04:35.890Z https://www.regulatoryrapporteur.org/a-comprehensive-analysis-of-drug-pricing-mechanisms-and-the-regulatory-framework-in-morocco/862.article 2025-04-09T11:41:29.800Z https://www.regulatoryrapporteur.org/deciphering-the-regulatory-landscape-of-mena-markets-challenges-in-pricing-and-ancillary-issues/863.article 2025-04-04T11:12:29.580Z https://www.regulatoryrapporteur.org/clinical-research-in-africa-regulatory-environment-challenges-and-opportunities/864.article 2025-04-09T10:46:38.473Z https://www.regulatoryrapporteur.org/regulatory-governance-for-medical-research-in-the-united-arab-emirates-a-comprehensive-overview/860.article 2026-03-05T16:49:35.337Z https://www.regulatoryrapporteur.org/essential-steps-for-a-successful-notified-body-application-in-medical-devices-and-in-vitro-diagnostic-products/861.article 2025-04-04T10:22:28.520Z https://www.regulatoryrapporteur.org/making-the-move-from-regulatory-affairs-transferring-your-skills-to-the-wider-pharmaceutical-industry/867.article 2025-04-04T10:22:45.973Z https://www.regulatoryrapporteur.org/podcasts/regrappod--inconversation-with-ivo-claassen/875.article 2025-08-15T10:41:21.357Z https://www.regulatoryrapporteur.org/industry-news/key-milestone-reached-in-african-medicines-regulation/874.article 2025-12-02T14:52:31.483Z https://www.regulatoryrapporteur.org/industry-news/mhra-provides-guidance-to-streamline-safety-communication/880.article 2025-12-02T14:54:19.353Z https://www.regulatoryrapporteur.org/interviews/how-to-develop-your-skills-and-stand-out-from-the-crowd/865.article 2025-06-19T12:06:51.180Z https://www.regulatoryrapporteur.org/interviews/how-to-inspire-a-new-generation-of-regulatory-professionals/866.article 2025-08-15T07:56:20.143Z https://www.regulatoryrapporteur.org/atmp/gene-therapy-medicinal-products-an-examination-of-regulatory-cmc-requirements/882.article 2026-03-04T18:10:34.677Z https://www.regulatoryrapporteur.org/may-2025-contents/891.article 2025-06-06T14:24:59.920Z https://www.regulatoryrapporteur.org/editorials/advanced-therapies-a-maturing-regulatory-framework/889.article 2025-06-06T14:43:01.860Z https://www.regulatoryrapporteur.org/case-studies-the-impact-of-the-in-vitro-diagnostic-regulation-on-atmp-clinical-trials-and-drug-development-plans/886.article 2026-03-04T18:10:32.500Z https://www.regulatoryrapporteur.org/atmp/recent-advances-and-the-near-term-outlook-for-advanced-therapy-medicinal-products-in-cancer-treatment/887.article 2026-03-04T18:10:33.793Z https://www.regulatoryrapporteur.org/navigating-orphan-drug-designation-in-the-eu/881.article 2025-05-02T14:19:58.127Z https://www.regulatoryrapporteur.org/artificial-intelligence/prescribing-efficiency-using-generative-artificial-intelligence-for-pharmacovigilance/883.article 2025-05-02T13:42:49.857Z https://www.regulatoryrapporteur.org/regulatory-procedures/navigating-the-fdas-platform-technology-designation-key-insights-and-best-practices-for-drug-manufacturers/884.article 2025-12-11T13:01:07.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-authorises-new-cancer-treatment-variation-with-significantly-reduced-administration-time/893.article 2025-12-02T14:58:08.797Z https://www.regulatoryrapporteur.org/free-prize-draw-terms-and-conditions/894.article 2025-05-09T16:45:38.250Z https://www.regulatoryrapporteur.org/industry-news/ema-to-address-antimicrobial-resistance-risks-from-veterinary-medicinal-products/896.article 2025-12-02T14:57:29.593Z https://www.regulatoryrapporteur.org/industry-news/fda-to-replace-animal-testing-with-new-approach-methodologies/897.article 2025-12-02T14:58:52.983Z https://www.regulatoryrapporteur.org/editorials/veterinary-medicines-translating-regulation-into-practice/904.article 2025-07-10T14:27:45.093Z https://www.regulatoryrapporteur.org/june-2025-contents/906.article 2025-06-06T14:42:53.623Z https://www.regulatoryrapporteur.org/promoting-the-use-of-bacteriophages-in-animals-to-reduce-antimicrobial-resistance/899.article 2025-06-06T14:31:17.267Z https://www.regulatoryrapporteur.org/new-european-medicines-agency-fees-the-effect-on-veterinary-medicines/900.article 2025-06-19T18:33:13.113Z https://www.regulatoryrapporteur.org/veterinary/veterinary-regulation-2019/6-impact-challenges-and-the-future-interview-with-ivo-claassen/901.article 2025-06-06T15:17:31.850Z https://www.regulatoryrapporteur.org/artificial-intelligence/sandbox-of-trust-regulated-ai-for-health-promotion-and-disease-prevention/902.article 2025-06-13T14:39:10.040Z https://www.regulatoryrapporteur.org/medical-device-standards-update-may-2025/898.article 2025-06-06T14:08:22.380Z https://www.regulatoryrapporteur.org/divergence-on-the-definition-of-regulatory-reliance-in-international-regions-is-there-room-for-convergence/903.article 2025-06-17T12:15:52.310Z https://www.regulatoryrapporteur.org/interviews/communicating-with-regulatory-affairs-professionals-the-power-of-the-podcast/876.article 2025-08-15T07:55:54.903Z https://www.regulatoryrapporteur.org/podcasts/regrappod--inconversation-with-hugues-malonne/913.article 2025-11-19T12:02:23.700Z https://www.regulatoryrapporteur.org/industry-news/updated-post-market-surveillance-requirements-take-effect/911.article 2025-06-20T15:26:12.917Z https://www.regulatoryrapporteur.org/interviews/famhp-the-role-of-the-belgian-agency-in-advancing-public-health/914.article 2025-08-15T07:55:21.550Z https://www.regulatoryrapporteur.org/industry-news/nhs-app-opens-access-to-trials-for-uk-patients/915.article 2025-06-25T14:26:45.453Z https://www.regulatoryrapporteur.org/industry-news/extension-to-icmra-post-approval-change-collaborative-pilots/916.article 2025-06-25T09:43:41.157Z https://www.regulatoryrapporteur.org/editorials/patient-voice-shaping-the-future-of-medicine-regulation/923.article 2025-09-04T15:35:24.623Z https://www.regulatoryrapporteur.org/regulatory-procedures/july/august-2025-contents/924.article 2025-11-19T11:41:00.707Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-evolving-landscape-of-public-and-patient-involvement/921.article 2025-08-12T13:37:13.603Z https://www.regulatoryrapporteur.org/clinical-trials/realising-opportunities-to-generate-rwe-for-regulatory-decisions-through-randomised-pragmatic-trials/917.article 2025-07-11T11:03:23.967Z https://www.regulatoryrapporteur.org/pharmaceuticals/patient-involvement-in-the-regulatory-area-insights-into-national-level-dialogues/918.article 2025-07-11T10:25:09.960Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-importance-of-patient-advocacy-in-the-ema-odd-process/922.article 2025-08-29T14:25:53.267Z https://www.regulatoryrapporteur.org/clinical-trials/diversity-in-clinical-research-regulatory-considerations-and-updates/920.article 2026-02-05T12:07:48.807Z https://www.regulatoryrapporteur.org/fda-comparability-guidance-the-impact-of-cell-and-gene-therapy-products/919.article 2025-07-11T10:26:10.210Z https://www.regulatoryrapporteur.org/interviews/the-importance-and-evolving-role-of-regulatory-affairs-education/878.article 2025-08-15T07:54:53.100Z https://www.regulatoryrapporteur.org/industry-news/nice-rejects-funding-for-lecanemab-as-treatment-benefits-remain-too-small/927.article 2025-07-18T08:36:48.553Z https://www.regulatoryrapporteur.org/industry-news/ema-and-ich-call-for-more-real-world-evidence-in-regulatory-practices/928.article 2025-07-18T14:49:35.987Z https://www.regulatoryrapporteur.org/industry-news/ema-publishes-workplan-on-how-to-harness-data-and-ai-for-public-health/929.article 2025-07-18T15:11:07.293Z https://www.regulatoryrapporteur.org/interviews/global-health-equity-inspiring-collaboration-and-harmonisation/879.article 2025-10-21T10:25:27.470Z https://www.regulatoryrapporteur.org/regulatory-careers-live/what-is-regulatory-affairs-how-does-it-fit-into-the-bigger-healthcare-picture-and-the-role-of-industry-in-the-regulatory-process/932.article 2025-08-18T13:35:43.650Z https://www.regulatoryrapporteur.org/regulatory-careers-live/regulatory-affairs-as-a-career/933.article 2025-08-15T11:47:25.673Z https://www.regulatoryrapporteur.org/regulatory-careers-live/the-job-search/934.article 2025-08-15T11:35:43.463Z https://www.regulatoryrapporteur.org/industry-news/fda-makes-labelling-changes-to-opioid-products-mandatory/935.article 2025-09-09T15:01:54.360Z https://www.regulatoryrapporteur.org/industry-news/new-director-appointed-at-the-fdas-center-for-drug-evaluation-and-research/936.article 2025-09-08T13:50:49.783Z https://www.regulatoryrapporteur.org/podcasts/regrappod--inconversation-with-zohra-nasir-and-aksa-rahman/938.article 2026-01-28T15:04:14.360Z https://www.regulatoryrapporteur.org/industry-news/efpia-publishes-guidance-document-to-help-support-novel-methodology-submissions/939.article 2025-08-15T08:03:50.767Z https://www.regulatoryrapporteur.org/product-information/translating-real-world-needs-into-digital-medication-tools-good-practices-for-co-creation-with-patients/944.article 2025-09-05T10:26:46.947Z https://www.regulatoryrapporteur.org/product-information/product-information-an-overview/947.article 2025-09-05T10:23:06.717Z https://www.regulatoryrapporteur.org/editorials/reimagining-product-information/948.article 2025-10-09T17:08:48.883Z https://www.regulatoryrapporteur.org/product-information/september-2025-contents/949.article 2025-09-05T10:37:40.163Z https://www.regulatoryrapporteur.org/product-information/the-ema/nca-electronic-product-information-initiative-engagement-implementation-and-vision-for-the-future/943.article 2025-09-08T15:44:25.350Z https://www.regulatoryrapporteur.org/product-information/electronic-patient-information-results-of-the-e-pil-pilot-from-belgium-and-luxembourg-hospitals/941.article 2025-09-05T10:25:24.300Z https://www.regulatoryrapporteur.org/product-information/-what-could-the-future-of-labelling-look-like-the-gravitate-health-story/942.article 2025-11-13T16:28:32.453Z https://www.regulatoryrapporteur.org/product-information/target-product-profile-and-product-profile-characteristics-for-labelling-during-drug-development/945.article 2025-09-05T10:36:52.710Z https://www.regulatoryrapporteur.org/product-information/digital-transformation-of-global-regulatory-affairs-then-now-and-next/946.article 2025-10-09T12:17:14.307Z https://www.regulatoryrapporteur.org/industry-news/survey-shapes-regulatory-rapporteurs-future-plans/951.article 2025-09-23T10:58:47.030Z https://www.regulatoryrapporteur.org/industry-news/nice-increases-access-to-sglt-2-inhibitors-medicines-to-help-treat-type-2-diabetes/953.article 2025-10-07T15:38:54.193Z https://www.regulatoryrapporteur.org/industry-news/ai-airlock-growing-the-future-of-artificial-intelligence-technology-in-healthcare/956.article 2025-12-11T13:01:03.283Z https://www.regulatoryrapporteur.org/interviews/how-to-advance-your-career-and-grow-with-the-industry/930.article 2025-09-22T09:26:28.720Z https://www.regulatoryrapporteur.org/industry-news/mhra-cross-agency-team-outlines-emerging-considerations-for-the-manufacture-of-personalised-medicines/955.article 2025-10-07T15:38:16.840Z https://www.regulatoryrapporteur.org/industry-news/regulatory-rapporteur-is-back-in-pdf-format/954.article 2025-10-10T10:26:55.043Z https://www.regulatoryrapporteur.org/editorials/from-trials-to-approval-regulatory-strategies-in-early-drug-development/968.article 2026-01-13T08:42:56.693Z https://www.regulatoryrapporteur.org/clinical-trials/central-sourcing-of-authorised-comparators-and-concomitant-medications-for-multiregional-clinical-trials-in-accordance-with-ich-e17-cmc-documentation-requirements/961.article 2025-12-11T12:44:25.310Z https://www.regulatoryrapporteur.org/clinical-trials/navigating-the-landscape-of-paediatric-clinical-trials-under-us-fda-guidelines/957.article 2026-03-05T16:49:36.640Z https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/maximising-regulatory-success-through-early-ema-engagement-in-drug-development/964.article 2025-10-10T11:13:51.967Z https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/ich-q1-guideline-revisions-to-promote-innovation-and-enable-global-patient-access-to-high-quality-medicines/965.article 2026-03-04T17:20:44.163Z https://www.regulatoryrapporteur.org/clinical-trials/the-use-of-prior-knowledge-and-platform-approaches-in-early-vaccine-development/960.article 2025-10-10T11:15:32.450Z https://www.regulatoryrapporteur.org/pharmaceuticals/probiotics-as-nutraceuticals-bridging-science-health-and-regulation/966.article 2025-12-11T12:43:22.537Z https://www.regulatoryrapporteur.org/interviews/leveraging-regulatory-science-expertise-for-next-generation-technologies/931.article 2025-10-23T13:56:12.500Z https://www.regulatoryrapporteur.org/industry-news/nice-reviews-health-technology-assessment-to-better-support-patients/970.article 2025-10-24T16:12:43.403Z https://www.regulatoryrapporteur.org/industry-news/mhra-cuts-approval-times-for-uk-clinical-trials-in-half/971.article 2025-10-24T09:02:16.140Z https://www.regulatoryrapporteur.org/industry-news/ema-launches-healthnothype-campaign/974.article 2025-10-24T16:38:38.967Z https://www.regulatoryrapporteur.org/clinical-trials/hm5/md1/ivd1-programme-combine-accelerating-clinical-trials-and-medical-innovation-in-the-eu/976.article 2025-11-18T13:59:21.660Z https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/hm6-how-artificial-intelligence-is-transforming-regulatory-approaches-towards-chemistry-manufacturing-and-controls-cmc/978.article 2025-11-18T14:00:14.393Z https://www.regulatoryrapporteur.org/editorials/topra-symposium-2025-leading-with-impact/1007.article 2025-11-18T12:49:08.563Z https://www.regulatoryrapporteur.org/regulatory-rapporteur-november-2025-contents/1009.article 2025-11-21T11:09:24.897Z https://www.regulatoryrapporteur.org/november-2025-contents-human-medicines-sessions/1010.article 2025-11-18T11:36:21.700Z https://www.regulatoryrapporteur.org/medical-devices/november-2025-contents-medical-devices/ivd-sessions/1011.article 2025-11-18T09:42:35.910Z https://www.regulatoryrapporteur.org/veterinary/november-2025-contents-veterinary-medicines-sessions/1012.article 2025-11-18T09:42:45.473Z https://www.regulatoryrapporteur.org/artificial-intelligence/hm1-general-pharmaceutical-legislation-platform-technology-and-sandbox-approaches/975.article 2025-11-18T13:56:22.930Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm2-fireside-chat/990.article 2025-11-18T13:57:14.033Z https://www.regulatoryrapporteur.org/artificial-intelligence/hm3-applying-artificial-intelligence-in-real-life/1006.article 2025-11-18T13:57:57.633Z https://www.regulatoryrapporteur.org/atmp/hm4-revision-of-the-eu-variation-regulation-continuing-innovation-in-lifecycle-management/977.article 2025-11-18T13:58:39.240Z https://www.regulatoryrapporteur.org/regulatory-procedures/hm7-first-experiences-with-the-hta-regulation/979.article 2026-04-07T14:57:22.597Z https://www.regulatoryrapporteur.org/product-information/hm8-epi-is-on-fhir-preparing-for-implementation/980.article 2025-11-18T14:01:31.063Z https://www.regulatoryrapporteur.org/atmp/hm9-from-barrier-to-bridge-practical-strategies-for-successful-advanced-therapy-medicinal-product-atmp-development/981.article 2026-03-04T18:10:31.260Z https://www.regulatoryrapporteur.org/clinical-trials/hm10-strengthening-europes-clinical-trials-competitiveness/982.article 2025-11-18T14:03:03.410Z https://www.regulatoryrapporteur.org/biologics/ps1-tailored-development-of-biosimilars-without-efficacy-and-safety-studies-is-this-the-future/984.article 2025-11-18T14:04:21.623Z https://www.regulatoryrapporteur.org/ps2-navigating-the-green-horizon-environmental-sustainability-and-regulatory-affairs/985.article 2025-11-18T14:04:54.907Z https://www.regulatoryrapporteur.org/regulatory-procedures/sme1-regulatory-updates-for-smes-academia-and-start-ups/986.article 2025-11-18T14:05:35.023Z https://www.regulatoryrapporteur.org/in-vitro-diagnostics/md2/ivd2-clinical-investigation-with-medical-devices/987.article 2025-11-18T14:08:09.537Z https://www.regulatoryrapporteur.org/medical-devices/md3/ivd3-a-global-snapshot-non-eu-regulatory-updates-for-medical-devices-and-ivds/988.article 2025-11-18T14:23:01.183Z https://www.regulatoryrapporteur.org/medical-devices/md4/ivd4-bridging-the-gaps-developments-in-medical-device-and-ivd-regulatory-harmonisation/989.article 2025-11-18T14:23:41.157Z https://www.regulatoryrapporteur.org/medical-devices/md5-the-evolution-of-the-eu-medical-device-regulation/992.article 2025-11-18T14:24:19.930Z https://www.regulatoryrapporteur.org/medical-devices/md6-the-importance-of-digital-health-digital-health-applications-diga-and-the-digital-mental-health-technology-project/993.article 2025-11-18T14:24:58.790Z https://www.regulatoryrapporteur.org/medical-devices/md7-updates-on-artificial-intelligence-legislation-and-policy/995.article 2025-11-18T11:33:19.870Z https://www.regulatoryrapporteur.org/medical-devices/md8-post-market-challenges-for-medical-devices/997.article 2025-11-18T14:25:37.137Z https://www.regulatoryrapporteur.org/medical-devices/ivd6-the-evolution-of-the-in-vitro-diagnostic-regulation/994.article 2025-11-18T14:26:13.913Z https://www.regulatoryrapporteur.org/in-vitro-diagnostics/ivd5-navigating-conformity-assessment-for-ivds-challenges-and-opportunities/1005.article 2025-11-18T14:26:54.260Z https://www.regulatoryrapporteur.org/medical-devices/ivd7-eu-reference-laboratories-under-the-ivdr-one-year-on/996.article 2025-11-18T14:27:36.880Z https://www.regulatoryrapporteur.org/medical-devices/ivd8-the-hunt-for-evidence-an-ivd-perspective/998.article 2025-11-18T14:29:35.937Z https://www.regulatoryrapporteur.org/veterinary-medicine/vm1-meeting-the-objectives-of-the-veterinary-regulation/999.article 2025-11-18T14:30:18.340Z https://www.regulatoryrapporteur.org/veterinary-medicine/vm2-regulatory-updates/1000.article 2025-11-18T14:30:54.750Z https://www.regulatoryrapporteur.org/veterinary-medicine/vm3-regulatory-updates-in-veterinary-pharmacovigilance-navigating-evolving-challenges/1001.article 2025-11-21T11:03:24.920Z https://www.regulatoryrapporteur.org/veterinary-medicine/vm4-the-latest-eu-and-international-developments-in-good-manufacturing-practice/1002.article 2025-11-18T14:32:06.373Z https://www.regulatoryrapporteur.org/veterinary-medicine/vm5-regulatory-considerations-for-novel-veterinary-therapies-antimicrobials-immunologicals-and-biologicals/1003.article 2025-11-18T14:32:54.660Z https://www.regulatoryrapporteur.org/veterinary-medicine/vm6-transitioning-to-animal-free-chemical-safety-testing-for-veterinary-medicines/1004.article 2025-11-18T14:34:12.973Z https://www.regulatoryrapporteur.org/industry-news/ema-etf-offers-scientific-advice-for-antimicrobial-resistance/1014.article 2025-11-25T12:30:05.400Z https://www.regulatoryrapporteur.org/industry-news/mhra-advances-new-reform-for-the-treatment-of-rare-diseases/1016.article 2025-11-25T12:29:35.393Z https://www.regulatoryrapporteur.org/industry-news/ema-launches-ittakesateam-campaign-to-address-medicine-shortages/1015.article 2025-11-25T12:29:48.927Z https://www.regulatoryrapporteur.org/editorials/north-america-transparency-transformation-and-innovation-pathways/1022.article 2025-12-15T15:53:40.027Z https://www.regulatoryrapporteur.org/regulatory-procedures/2025-regulatory-intelligence-conference-europe-meeting-report/1023.article 2025-12-15T16:00:33.300Z https://www.regulatoryrapporteur.org/software/bridging-the-digital-divide-a-toolkit-for-equity-centred-regulation-of-digital-mental-health/1025.article 2025-12-15T15:59:02.820Z https://www.regulatoryrapporteur.org/pharmaceuticals/from-laboratory-to-patient-the-role-of-new-substance-notifications-in-delivering-innovative-therapies-in-canada/1026.article 2025-12-15T15:54:17.630Z https://www.regulatoryrapporteur.org/regulatory-procedures/cross-functional-strategies-in-clinical-data-disclosure-for-ema-policy-0070-and-health-canada-prci/1019.article 2025-12-15T16:13:20.610Z https://www.regulatoryrapporteur.org/a-year-of-change-for-the-us-fda-an-update-on-notable-pilots-and-programmes/1020.article 2025-12-15T16:06:53.750Z https://www.regulatoryrapporteur.org/medical-devices/bringing-innovation-to-market-regulatory-strategy-for-medtech-companies/1021.article 2025-12-17T12:42:47.153Z https://www.regulatoryrapporteur.org/medical-devices/medical-device-standards-update-december-2025/1017.article 2025-12-15T15:59:58.740Z https://www.regulatoryrapporteur.org/industry-news/darwin-eu-reaches-more-than-100-research-studies/1029.article 2025-12-22T11:58:15.183Z https://www.regulatoryrapporteur.org/industry-news/the-vmd-changes-how-it-calculates-adverse-events-incidents-for-animals/1031.article 2025-12-18T16:08:00.017Z https://www.regulatoryrapporteur.org/industry-news/ec-proposes-regulation-to-simplify-rules-on-medical-and-in-vitro-diagnostic-devices/1032.article 2025-12-22T12:46:39.103Z https://www.regulatoryrapporteur.org/industry-news/saudi-fda-vision-to-be-a-leading-regulator-includes-updating-guidance-on-combination-products/1030.article 2025-12-22T13:23:16.043Z